This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oesterreich, S. Articles by Lee, A. V. Search for Related Content PubMed PubMed Citation Articles by Oesterreich, S. Articles by Lee, A. V.

Tamoxifen-Bound Estrogen Receptor (ER) Strongly Interacts with the Nuclear Matrix Protein HET/SAF-B, a Novel Inhibitor of ER-Mediated Transactivation

Department of Medicine (S.O., Q.Z., T.H., S.A.W.F., M.M., H.H.Z., C.K.O., A.V.L.) Division of Oncology University of Texas Health Science Center San Antonio, Texas 78284
Department of Biochemistry and Molecular Biology (J.R.D.) University of Manitoba Winnipeg, Manitoba, Canada R3E 0W3

The estrogen receptor (ER) is a ligand-dependent transcription factor that acts in a cell- and promoter-specific manner. Evidence suggests that the activity of the ER can be regulated by a number of other stimuli (e.g. growth factors) and that the effects of the ER are modulated by nuclear factors termed coregulators. While the interplay among these factors may in part explain the pleiotropic effects elicited by the ER, there are several other less well described mechanisms of control, such as interactions with the nuclear matrix. Here we report that the nuclear matrix protein/scaffold attachment factor HET/SAF-B is an ER-interacting protein. ER and HET/SAF-B interact in in vitro binding assays, with HET binding to both the ER DNA-binding domain and the hinge region. Coimmunoprecipitation experiments reveal that HET/SAF-B and ER associate in cell lines in the presence or absence of estradiol, but binding is increased by the antiestrogen tamoxifen. HET/SAF-B enhances tamoxifen antagonism of estrogen-induced ER-mediated transactivation, but at high concentrations can inhibit both estrogen and tamoxifen-induced ER activity. HET/SAF-B-mediated repression of ER activity is dependent upon interaction with the ER-DBD. While the existence of high-affinity binding sites for the ER in the nuclear matrix has been known for some time, we now provide evidence of a specific nuclear matrix protein binding to the ER. Furthermore, our data showing that HET/SAF-B binds to ER particularly strongly in the presence of tamoxifen suggests that it may be important for the antagonist effect of tamoxifen.

This article has been cited by other articles:

				N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Strom, E. Treuter, M. Warner, et al. Estrogen Receptors: How Do They Signal and What Are Their Targets Physiol Rev, July 1, 2007; 87(3): 905 - 931. [Abstract] [Full Text] [PDF]

				K. A. Sergeant, C. F. Bourgeois, C. Dalgliesh, J. P. Venables, J. Stevenin, and D. J. Elliott Alternative RNA splicing complexes containing the scaffold attachment factor SAFB2 J. Cell Sci., January 15, 2007; 120(2): 309 - 319. [Abstract] [Full Text] [PDF]

				C. Das, K. Hizume, K. Batta, B. R. P. Kumar, S. S. Gadad, S. Ganguly, S. Lorain, A. Verreault, P. P. Sadhale, K. Takeyasu, et al. Transcriptional Coactivator PC4, a Chromatin-Associated Protein, Induces Chromatin Condensation Mol. Cell. Biol., November 15, 2006; 26(22): 8303 - 8315. [Abstract] [Full Text] [PDF]

				Y. Cui, A. Niu, R. Pestell, R. Kumar, E. M. Curran, Y. Liu, and S. A. W. Fuqua Metastasis-Associated Protein 2 Is a Repressor of Estrogen Receptor {alpha} Whose Overexpression Leads to Estrogen-Independent Growth of Human Breast Cancer Cells Mol. Endocrinol., September 1, 2006; 20(9): 2020 - 2035. [Abstract] [Full Text] [PDF]

				K. M. Dobrzycka, K. Kang, S. Jiang, R. Meyer, P. H. Rao, A. V. Lee, and S. Oesterreich Disruption of Scaffold Attachment Factor B1 Leads to TBX2 Up-regulation, Lack of p19ARF Induction, Lack of Senescence, and Cell Immortalization Cancer Res., August 15, 2006; 66(16): 7859 - 7863. [Abstract] [Full Text] [PDF]

				S. Jiang, R. Meyer, K. Kang, C. K. Osborne, J. Wong, and S. Oesterreich Scaffold Attachment Factor SAFB1 Suppresses Estrogen Receptor {alpha}-Mediated Transcription in Part via Interaction with Nuclear Receptor Corepressor Mol. Endocrinol., February 1, 2006; 20(2): 311 - 320. [Abstract] [Full Text] [PDF]

				M-B Debril, L Dubuquoy, J-N Feige, W Wahli, B Desvergne, J Auwerx, and L Gelman Scaffold attachment factor B1 directly interacts with nuclear receptors in living cells and represses transcriptional activity J. Mol. Endocrinol., December 1, 2005; 35(3): 503 - 517. [Abstract] [Full Text] [PDF]

				E. K. Keeton and M. Brown Cell Cycle Progression Stimulated by Tamoxifen-Bound Estrogen Receptor-{alpha} and Promoter-Specific Effects in Breast Cancer Cells Deficient in N-CoR and SMRT Mol. Endocrinol., June 1, 2005; 19(6): 1543 - 1554. [Abstract] [Full Text] [PDF]

				J. N. Feige, L. Gelman, C. Tudor, Y. Engelborghs, W. Wahli, and B. Desvergne Fluorescence Imaging Reveals the Nuclear Behavior of Peroxisome Proliferator-activated Receptor/Retinoid X Receptor Heterodimers in the Absence and Presence of Ligand J. Biol. Chem., May 6, 2005; 280(18): 17880 - 17890. [Abstract] [Full Text] [PDF]

				M. Ivanova, K. M. Dobrzycka, S. Jiang, K. Michaelis, R. Meyer, K. Kang, B. Adkins, O. A. Barski, S. Zubairy, J. Divisova, et al. Scaffold Attachment Factor B1 Functions in Development, Growth, and Reproduction Mol. Cell. Biol., April 15, 2005; 25(8): 2995 - 3006. [Abstract] [Full Text] [PDF]

				S. A. Lee, D. Ndisang, C. Patel, J. H. Dennis, D. J. Faulkes, C. D'Arrigo, L. Samady, S. Farooqui-Kabir, R. J. Heads, D. S. Latchman, et al. Expression of the Brn-3b Transcription Factor Correlates with Expression of HSP-27 in Breast Cancer Biopsies and Is Required for Maximal Activation of the HSP-27 Promoter Cancer Res., April 15, 2005; 65(8): 3072 - 3080. [Abstract] [Full Text] [PDF]

				Y. Cui, M. Zhang, R. Pestell, E. M. Curran, W. V. Welshons, and S. A. W. Fuqua Phosphorylation of Estrogen Receptor {alpha} Blocks Its Acetylation and Regulates Estrogen Sensitivity Cancer Res., December 15, 2004; 64(24): 9199 - 9208. [Abstract] [Full Text] [PDF]

				S. M. Townson, K. Kang, A. V. Lee, and S. Oesterreich Structure-Function Analysis of the Estrogen Receptor {alpha} Corepressor Scaffold Attachment Factor-B1: IDENTIFICATION OF A POTENT TRANSCRIPTIONAL REPRESSION DOMAIN J. Biol. Chem., June 18, 2004; 279(25): 26074 - 26081. [Abstract] [Full Text] [PDF]

				J. Shou, S. Massarweh, C. K. Osborne, A. E. Wakeling, S. Ali, H. Weiss, and R. Schiff Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer J Natl Cancer Inst, June 16, 2004; 96(12): 926 - 935. [Abstract] [Full Text] [PDF]

				N. Heldring, M. Nilsson, B. Buehrer, E. Treuter, and J.-A. Gustafsson Identification of Tamoxifen-Induced Coregulator Interaction Surfaces within the Ligand-Binding Domain of Estrogen Receptors Mol. Cell. Biol., April 15, 2004; 24(8): 3445 - 3459. [Abstract] [Full Text] [PDF]

				V. Marsaud, A. Gougelet, S. Maillard, and J.-M. Renoir Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor {alpha} (ER{alpha}), Differentially Affect ER{alpha} Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells Mol. Endocrinol., October 1, 2003; 17(10): 2013 - 2027. [Abstract] [Full Text] [PDF]

				S. Oesterreich, W. Deng, S. Jiang, X. Cui, M. Ivanova, R. Schiff, K. Kang, D. L. Hadsell, J. Behrens, and A. V. Lee Estrogen-mediated Down-Regulation of E-cadherin in Breast Cancer Cells Cancer Res., September 1, 2003; 63(17): 5203 - 5208. [Abstract] [Full Text] [PDF]

				S. M. Townson, K. M. Dobrzycka, A. V. Lee, M. Air, W. Deng, K. Kang, S. Jiang, N. Kioka, K. Michaelis, and S. Oesterreich SAFB2, a New Scaffold Attachment Factor Homolog and Estrogen Receptor Corepressor J. Biol. Chem., May 23, 2003; 278(22): 20059 - 20068. [Abstract] [Full Text] [PDF]

				P. Webb, P. Nguyen, and P. J. Kushner Differential SERM Effects on Corepressor Binding Dictate ERalpha Activity in Vivo J. Biol. Chem., February 21, 2003; 278(9): 6912 - 6920. [Abstract] [Full Text] [PDF]

				J.-A. Tan, S. H. Hall, K. G. Hamil, G. Grossman, P. Petrusz, and F. S. French Protein Inhibitors of Activated STAT Resemble Scaffold Attachment Factors and Function as Interacting Nuclear Receptor Coregulators J. Biol. Chem., May 3, 2002; 277(19): 16993 - 17001. [Abstract] [Full Text] [PDF]

				M. Fan, X. Long, J. A. Bailey, C. A. Reed, E. Osborne, E. A. Gize, E. A. Kirk, R. M. Bigsby, and K. P. Nephew The Activating Enzyme of NEDD8 Inhibits Steroid Receptor Function Mol. Endocrinol., February 1, 2002; 16(2): 315 - 330. [Abstract] [Full Text] [PDF]

				S. Oesterreich, P. Zhang, R. L. Guler, X. Sun, E. M. Curran, W. V. Welshons, C. K. Osborne, and A. V. Lee Re-expression of Estrogen Receptor {alpha} in Estrogen Receptor {alpha}-negative MCF-7 Cells Restores both Estrogen and Insulin-like Growth Factor-mediated Signaling and Growth Cancer Res., August 1, 2001; 61(15): 5771 - 5777. [Abstract] [Full Text] [PDF]

				N. Kotaja, S. Aittomäki, O. Silvennoinen, J. J. Palvimo, and O. A. Jänne ARIP3 (Androgen Receptor-Interacting Protein 3) and Other PIAS (Protein Inhibitor of Activated STAT) Proteins Differ in Their Ability to Modulate Steroid Receptor-Dependent Transcriptional Activation Mol. Endocrinol., December 1, 2000; 14(12): 1986 - 2000. [Abstract] [Full Text]

				M. Dutertre and C. L. Smith Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 431 - 437. [Abstract] [Full Text]

				S. M. Townson, T. Sullivan, Q. Zhang, G. M. Clark, C. K. Osborne, A. V. Lee, and S. Oesterreich HET/SAF-B Overexpression Causes Growth Arrest and Multinuclearity and Is Associated with Aneuploidy in Human Breast Cancer Clin. Cancer Res., September 1, 2000; 6(9): 3788 - 3796. [Abstract] [Full Text]